The decreased Treg population resulted in a higher CD8+/Treg ratio in the NTP treatment group (1.18‐fold increase; p = 0.0414), thus pointing to a stronger activating, anti‐cancer immune response (Figure 5c). The gene discussed is CD8A; the disease is cancer.